NASDAQ:RDHL

RedHill Biopharma Competitors

$7.10
-0.28 (-3.79 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.95
Now: $7.10
$7.31
50-Day Range
$6.71
MA: $7.68
$9.94
52-Week Range
$5.93
Now: $7.10
$11.52
Volume300,854 shs
Average Volume557,992 shs
Market Capitalization$329.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Competitors

RedHill Biopharma (NASDAQ:RDHL) Vs. CMPS, STTK, RPTX, DVAX, OCUL, and KRON

Should you be buying RDHL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to RedHill Biopharma, including COMPASS Pathways (CMPS), Shattuck Labs (STTK), Repare Therapeutics (RPTX), Dynavax Technologies (DVAX), Ocular Therapeutix (OCUL), and Kronos Bio (KRON).

COMPASS Pathways (NASDAQ:CMPS) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for COMPASS Pathways and RedHill Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
COMPASS Pathways00603.00
RedHill Biopharma00303.00

COMPASS Pathways currently has a consensus target price of $70.75, suggesting a potential upside of 105.97%. RedHill Biopharma has a consensus target price of $20.00, suggesting a potential upside of 181.69%. Given RedHill Biopharma's higher probable upside, analysts plainly believe RedHill Biopharma is more favorable than COMPASS Pathways.

Profitability

This table compares COMPASS Pathways and RedHill Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
COMPASS PathwaysN/AN/AN/A
RedHill Biopharma-142.81%-152.19%-45.96%

Insider and Institutional Ownership

15.8% of COMPASS Pathways shares are held by institutional investors. Comparatively, 20.4% of RedHill Biopharma shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares COMPASS Pathways and RedHill Biopharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A
RedHill Biopharma$6.29 million52.37$-42,300,000.00($1.40)-5.07

COMPASS Pathways has higher earnings, but lower revenue than RedHill Biopharma.

Summary

COMPASS Pathways beats RedHill Biopharma on 5 of the 8 factors compared between the two stocks.

RedHill Biopharma (NASDAQ:RDHL) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for RedHill Biopharma and Shattuck Labs, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RedHill Biopharma00303.00
Shattuck Labs00603.00

RedHill Biopharma currently has a consensus target price of $20.00, indicating a potential upside of 181.69%. Shattuck Labs has a consensus target price of $45.60, indicating a potential upside of 51.95%. Given RedHill Biopharma's higher probable upside, analysts clearly believe RedHill Biopharma is more favorable than Shattuck Labs.

Profitability

This table compares RedHill Biopharma and Shattuck Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RedHill Biopharma-142.81%-152.19%-45.96%
Shattuck LabsN/AN/AN/A

Institutional and Insider Ownership

20.4% of RedHill Biopharma shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares RedHill Biopharma and Shattuck Labs' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RedHill Biopharma$6.29 million52.37$-42,300,000.00($1.40)-5.07
Shattuck LabsN/AN/AN/AN/AN/A

Shattuck Labs has lower revenue, but higher earnings than RedHill Biopharma.

Summary

Shattuck Labs beats RedHill Biopharma on 4 of the 7 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations for Repare Therapeutics and RedHill Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repare Therapeutics01513.00
RedHill Biopharma00303.00

Repare Therapeutics currently has a consensus price target of $39.40, indicating a potential upside of 16.98%. RedHill Biopharma has a consensus price target of $20.00, indicating a potential upside of 181.69%. Given RedHill Biopharma's higher possible upside, analysts clearly believe RedHill Biopharma is more favorable than Repare Therapeutics.

Profitability

This table compares Repare Therapeutics and RedHill Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repare TherapeuticsN/AN/AN/A
RedHill Biopharma-142.81%-152.19%-45.96%

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of RedHill Biopharma shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Repare Therapeutics and RedHill Biopharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare TherapeuticsN/AN/AN/AN/AN/A
RedHill Biopharma$6.29 million52.37$-42,300,000.00($1.40)-5.07

Repare Therapeutics has higher earnings, but lower revenue than RedHill Biopharma.

Summary

Repare Therapeutics beats RedHill Biopharma on 6 of the 8 factors compared between the two stocks.

RedHill Biopharma (NASDAQ:RDHL) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Profitability

This table compares RedHill Biopharma and Dynavax Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RedHill Biopharma-142.81%-152.19%-45.96%
Dynavax Technologies-256.92%-193.85%-23.45%

Analyst Ratings

This is a breakdown of recent recommendations for RedHill Biopharma and Dynavax Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RedHill Biopharma00303.00
Dynavax Technologies00403.00

RedHill Biopharma currently has a consensus target price of $20.00, indicating a potential upside of 181.69%. Dynavax Technologies has a consensus target price of $16.3333, indicating a potential upside of 48.62%. Given RedHill Biopharma's higher possible upside, equities analysts plainly believe RedHill Biopharma is more favorable than Dynavax Technologies.

Insider and Institutional Ownership

20.4% of RedHill Biopharma shares are held by institutional investors. Comparatively, 80.0% of Dynavax Technologies shares are held by institutional investors. 13.3% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares RedHill Biopharma and Dynavax Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RedHill Biopharma$6.29 million52.37$-42,300,000.00($1.40)-5.07
Dynavax Technologies$35.22 million35.34$-152,600,000.00($1.87)-5.88

RedHill Biopharma has higher earnings, but lower revenue than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than RedHill Biopharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

RedHill Biopharma has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Summary

RedHill Biopharma beats Dynavax Technologies on 8 of the 13 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 20.4% of RedHill Biopharma shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Ocular Therapeutix and RedHill Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocular Therapeutix-780.19%-14,065.71%-81.81%
RedHill Biopharma-142.81%-152.19%-45.96%

Risk and Volatility

Ocular Therapeutix has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Ocular Therapeutix and RedHill Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocular Therapeutix01213.00
RedHill Biopharma00303.00

Ocular Therapeutix currently has a consensus price target of $24.80, indicating a potential upside of 56.07%. RedHill Biopharma has a consensus price target of $20.00, indicating a potential upside of 181.69%. Given RedHill Biopharma's higher probable upside, analysts plainly believe RedHill Biopharma is more favorable than Ocular Therapeutix.

Valuation & Earnings

This table compares Ocular Therapeutix and RedHill Biopharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$4.23 million285.76$-86,370,000.00($2.01)-7.91
RedHill Biopharma$6.29 million52.37$-42,300,000.00($1.40)-5.07

RedHill Biopharma has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than RedHill Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

RedHill Biopharma beats Ocular Therapeutix on 9 of the 14 factors compared between the two stocks.

Kronos Bio (NASDAQ:KRON) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Institutional and Insider Ownership

20.4% of RedHill Biopharma shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Kronos Bio and RedHill Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kronos BioN/AN/AN/A
RedHill Biopharma-142.81%-152.19%-45.96%

Valuation & Earnings

This table compares Kronos Bio and RedHill Biopharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kronos BioN/AN/AN/AN/AN/A
RedHill Biopharma$6.29 million52.37$-42,300,000.00($1.40)-5.07

Kronos Bio has higher earnings, but lower revenue than RedHill Biopharma.

Analyst Ratings

This is a summary of recent ratings and price targets for Kronos Bio and RedHill Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kronos Bio00403.00
RedHill Biopharma00303.00

Kronos Bio currently has a consensus target price of $43.6667, suggesting a potential upside of 102.54%. RedHill Biopharma has a consensus target price of $20.00, suggesting a potential upside of 181.69%. Given RedHill Biopharma's higher possible upside, analysts clearly believe RedHill Biopharma is more favorable than Kronos Bio.

Summary

Kronos Bio beats RedHill Biopharma on 4 of the 7 factors compared between the two stocks.


RedHill Biopharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43-1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51-6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41-2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.34-1.0%$950.61 millionN/A-12.60
Radius Health logo
RDUS
Radius Health
1.1$19.71-0.2%$924.28 million$173.32 million-8.08
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.45-0.5%$897.94 millionN/A0.00
Annexon logo
ANNX
Annexon
1.9$23.42-2.2%$893.66 millionN/A0.00Increase in Short Interest
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.95-0.1%$858.83 millionN/A-10.37Analyst Report
News Coverage
Merus logo
MRUS
Merus
1.6$22.52-1.7%$858.62 million$31.13 million-7.34Analyst Report
Ardelyx logo
ARDX
Ardelyx
1.6$8.69-0.3%$857.53 million$5.28 million-8.60High Trading Volume
Unusual Options Activity
News Coverage
Affimed logo
AFMD
Affimed
1.6$9.51-0.3%$839.98 million$23.96 million-16.12Earnings Announcement
News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$24.82-5.4%$838.42 millionN/A-22.98
Epizyme logo
EPZM
Epizyme
1.8$8.10-1.6%$824.46 million$23.80 million-3.63
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.30-0.3%$820.59 million$322.36 million123.57
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.27-0.8%$819.20 million$296.70 million47.49Analyst Revision
News Coverage
Humanigen logo
HGEN
Humanigen
1.7$14.73-5.6%$787.79 millionN/A0.00Increase in Short Interest
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.33-2.7%$782.70 millionN/A0.00Increase in Short Interest
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.02-0.1%$755.02 million$148.36 million-7.02Analyst Revision
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.05-3.2%$728.99 million$322.07 million-4.81Decrease in Short Interest
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.71-0.2%$728.84 million$40.89 million-3.35
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.63-1.9%$702.93 million$6.83 million-20.24
Chimerix logo
CMRX
Chimerix
1.3$8.18-1.6%$700.85 million$12.52 million-14.35Analyst Upgrade
Increase in Short Interest
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.